Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Sabrina Borchert"'
Autor:
Elena Mairinger, Michael Wessolly, Paul Buderath, Sabrina Borchert, Larissa Henrich, Pawel Mach, Julia Steinborn, Rainer Kimming, Bharat Jasani, Kurt Werner Schmid, Agnes Bankfalvi, Fabian Dominik Mairinger
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundThe underlying mechanism of high T-cell presence as a favorable prognostic factor in high-grade serous ovarian carcinoma (HGSOC) is not yet understood. In addition to immune cells, various cofactors are essential for immune processes. One o
Externí odkaz:
https://doaj.org/article/61da0f0817b3496bb034186b8ace0936
Autor:
Michael Wessolly, Susann Stephan-Falkenau, Anna Streubel, Marcel Wiesweg, Sabrina Borchert, Elena Mairinger, Jens Kollmeier, Henning Reis, Torsten Bauer, Kurt Werner Schmid, Thomas Mairinger, Martin Schuler, Fabian D. Mairinger
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-13 (2022)
Abstract Background Immune checkpoint inhibitors (ICIs) are currently one of the most promising therapy options in the field of oncology. Although the first pivotal ICI trial results were published in 2011, few biomarkers exist to predict their thera
Externí odkaz:
https://doaj.org/article/ba9aee6c71794d6f8106a205ed38e4c9
Autor:
Sabrina Borchert, Alexander Mathilakathu, Alina Nath, Michael Wessolly, Elena Mairinger, Daniel Kreidt, Julia Steinborn, Robert F. H. Walter, Daniel C. Christoph, Jens Kollmeier, Jeremias Wohlschlaeger, Thomas Mairinger, Luka Brcic, Fabian D. Mairinger
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 15, p 12426 (2023)
The exact mechanism of desmoplastic stromal reaction (DSR) formation is still unclear. The interaction between cancer cells and cancer-associated fibroblasts (CAFs) has an important role in tumor progression, while stromal changes are a poor prognost
Externí odkaz:
https://doaj.org/article/e183de99799c44e0a585e5da333f4d6d
Autor:
Thomas Hager, Sabrina Borchert, Michael Wessolly, Alexander Mathilakathu, Elena Mairinger, Jens Kollmeier, Thomas Mairinger, Balazs Hegedus, Kristina Greimelmaier, Jeremias Wohlschlaeger, Ken Herrmann, Fabian Dominik Mairinger
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 7, p 6356 (2023)
Malignant pleural mesothelioma (MPM) is a mainly asbestos-related tumour associated with a very poor prognosis. Therapeutic approaches include multimodal therapy and chemotherapeutics, with cisplatin being the drug of choice, but response rates of on
Externí odkaz:
https://doaj.org/article/af62e333fb3b4b25b1feb1a0f7945c79
Autor:
Michael Wessolly, Elena Mairinger, Sabrina Borchert, Agnes Bankfalvi, Pawel Mach, Kurt Werner Schmid, Rainer Kimmig, Paul Buderath, Fabian Dominik Mairinger
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundHigh-grade serous ovarian cancer (HGSOC) is the predominant and deadliest form of ovarian cancer. Some of its histological subtypes can be distinguished by frequent occurrence of cancer-associated myofibroblasts (CAFs) and desmoplastic stro
Externí odkaz:
https://doaj.org/article/2d03341162de4358a573bb7f97a982f0
Autor:
Sabrina Borchert, Michael Wessolly, Jan Schmeller, Elena Mairinger, Jens Kollmeier, Thomas Hager, Thomas Mairinger, Thomas Herold, Daniel C. Christoph, Robert F. H. Walter, Wilfried E. E. Eberhardt, Till Plönes, Jeremias Wohlschlaeger, Clemens Aigner, Kurt Werner Schmid, Fabian D. Mairinger
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-12 (2019)
Abstract Background Malignant pleural mesothelioma (MPM) is a tumour arising from pleural cavities with poor prognosis. Multimodality treatment with pemetrexed combined with cisplatin shows unsatisfying response-rates of 40%. The reasons for the rath
Externí odkaz:
https://doaj.org/article/a78dfbb5af2449eea6d8fb6a3f276409
Autor:
Alexander Mathilakathu, Michael Wessolly, Elena Mairinger, Hendrik Uebner, Daniel Kreidt, Luka Brcic, Julia Steinborn, Kristina Greimelmaier, Jeremias Wohlschlaeger, Kurt Werner Schmid, Fabian D. Mairinger, Sabrina Borchert
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 6, p 3278 (2022)
Background: Malignant pleural mesothelioma (MPM) has an infaust prognosis due to resistance to systemic treatment with platin-analoga. MPM cells modulate the immune response to their benefit. They release proinflammatory cytokines, such as TGF-ß, aw
Externí odkaz:
https://doaj.org/article/51fa2fd03a724f49a8bcc233ecaae0ee
Autor:
Sabrina Borchert, Thomas Herold, Stavros Kalbourtzis, Rainer Hamacher, Yvonne Krause, Sophia Berger, Wiebke K. Guder, Arne Streitbuerger, Jendrik Hardes, Moritz Goetz, Sebastian Bauer, Hans-Ulrich Schildhaus
Publikováno v:
Cancers; Volume 14; Issue 19; Pages: 4737
OA Förderung 2022 Background: Transcriptome profiling provides large data on tumor biology, which is particularly valuable in translational research and is becoming more and more important for clinical decision-making as well. RNA sequencing is cons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd63654ce53e110064b44fa24362a9d9
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85139851697
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85139851697
Autor:
Thomas Herold, Wildfried E. E. Eberhardt, Pia-Maria Suckrau, Jeremias Wohlschlaeger, Clemens Aigner, Kurt Werner Schmid, Agnes Bankfalvi, Michael Wessolly, Fabian Dominik Mairinger, Robert Fred Henry Walter, Elena Mairinger, Balazs Hegedus, Thomas Hager, Sabrina Borchert
Publikováno v:
Journal of Oncology, Vol 2019 (2019)
Journal of Oncology
Journal of Oncology
Background. Malignant pleural mesothelioma (MPM) is a rare, predominantly asbestos-related and biologically highly aggressive tumor associated with a dismal prognosis. Multimodal therapy consisting of platinum-based chemotherapy is the treatment of c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b0c8a4ac774f736984f0d5f26ef6fda
https://doi.org/10.1155/2019/2902985
https://doi.org/10.1155/2019/2902985
Autor:
Michael Wessolly, Susann Stephan-Falkenau, Anna Streubel, Marcel Wiesweg, Sabrina Borchert, Elena Mairinger, Jens Kollmeier, Henning Reis, Torsten Bauer, Kurt Werner Schmid, Thomas Mairinger, Martin Schuler, Fabian D. Mairinger
Publikováno v:
BMC Cancer
BMC Cancer, Vol 22, Iss 1, Pp 1-13 (2022)
BMC Cancer, Vol 22, Iss 1, Pp 1-13 (2022)
Background Immune checkpoint inhibitors (ICIs) are currently one of the most promising therapy options in the field of oncology. Although the first pivotal ICI trial results were published in 2011, few biomarkers exist to predict their therapy outcom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ffce579c84d14134fc09ed2afd2bef7
https://pubmed.ncbi.nlm.nih.gov/34996407
https://pubmed.ncbi.nlm.nih.gov/34996407